List of Excipients in Branded Drug STIVARGA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare Pharmaceuticals Inc	STIVARGA	regorafenib	50419-171	CELLULOSE, MICROCRYSTALLINE	2031-04-08
Bayer HealthCare Pharmaceuticals Inc	STIVARGA	regorafenib	50419-171	CROSCARMELLOSE SODIUM	2031-04-08
Bayer HealthCare Pharmaceuticals Inc	STIVARGA	regorafenib	50419-171	FERRIC OXIDE RED	2031-04-08
Bayer HealthCare Pharmaceuticals Inc	STIVARGA	regorafenib	50419-171	FERRIC OXIDE YELLOW	2031-04-08
Bayer HealthCare Pharmaceuticals Inc	STIVARGA	regorafenib	50419-171	MAGNESIUM STEARATE	2031-04-08

STIVARGA Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

STIVARGA (regorafenib) is an oral, immediate-release film-coated tablet with a relatively simple excipient system. The main commercial opportunities are not in copying the branded tablet’s excipients. They are in improving dissolution, reducing food-effect sensitivity, supporting generic bioequivalence, lowering manufacturing cost, and developing differentiated regorafenib delivery systems. Because regorafenib is a small molecule, the principal competitive pathway is generic substitution, not biosimilar competition.

What is STIVARGA and how is it administered?

STIVARGA contains regorafenib, a multikinase inhibitor approved in the United States for metastatic colorectal cancer, unresectable or metastatic gastrointestinal stromal tumor after prior treatment, and hepatocellular carcinoma after prior sorafenib therapy.[1]

Attribute	STIVARGA profile
Active ingredient	Regorafenib
Drug class	Oral multikinase inhibitor
Strength	40 mg per tablet
Standard adult dose	160 mg once daily
Treatment cycle	21 days on treatment, followed by 7 days off
Dosage form	Immediate-release film-coated tablet
Administration	After a low-fat meal
U.S. sponsor	Bayer HealthCare Pharmaceuticals
FDA approval	2012 for metastatic colorectal cancer
Additional indications	GIST in 2013; hepatocellular carcinoma in 2017
Generic pathway	Abbreviated New Drug Application, or ANDA
Biosimilar pathway	Not applicable

The approved regimen requires four 40 mg tablets per daily dose. That creates a practical opportunity for alternative strengths, dose-pack configurations, adherence packaging, and tablet-count optimization, although any change would require regulatory support.

What excipients are used in STIVARGA tablets?

The U.S. prescribing information identifies the inactive ingredients used in STIVARGA tablets. The core tablet includes conventional direct-compression and film-coating materials.[1]

Formulation component	Function
Microcrystalline cellulose	Diluent and compression aid
Croscarmellose sodium	Superdisintegrant
Povidone	Binder
Colloidal silicon dioxide	Glidant and moisture-control aid
Magnesium stearate	Lubricant
Hypromellose	Film-coating polymer
Titanium dioxide	Opacifier and pigment
Ferric oxide pigments	Tablet-color system

The formulation is commercially conservative. It uses widely available excipients with established pharmaceutical supply chains. This reduces formulation complexity and supports conventional tablet manufacturing.

The public label does not establish that any individual excipient produces a proprietary commercial advantage. The value of the formulation is more likely to arise from the combination of particle properties, granulation conditions, compression parameters, coating process, dissolution profile, and control of regorafenib’s low aqueous solubility.

Why is regorafenib an excipient-development opportunity?

Regorafenib presents a formulation challenge because it has low aqueous solubility and requires clinically controlled exposure. The product label also requires administration after a low-fat meal, indicating that gastrointestinal conditions and food composition affect systemic exposure.[1]

The main formulation risks are:

1. Incomplete or variable dissolution.
2. Sensitivity to active-ingredient particle size and solid form.
3. Food-related changes in absorption.
4. High tablet burden at the standard 160 mg daily dose.
5. Exposure-related adverse events, including hand-foot skin reaction, hypertension, diarrhea, fatigue, and hepatotoxicity.

An excipient platform that increases dissolution without increasing peak exposure excessively could have commercial value. A formulation that improves exposure consistency across fed and fasted conditions could have greater clinical and regulatory value, but it would also create a more demanding bioequivalence program.

What excipient strategies could improve STIVARGA performance?

Amorphous solid dispersion

A polymer-based amorphous solid dispersion could improve apparent solubility and dissolution. Candidate polymers may include hypromellose-based systems, hypromellose acetate succinate, polyvinylpyrrolidone, or copovidone.

The commercial advantages would include:

• Higher dissolution at physiologically relevant pH.
• Potentially lower variability between patients.
• A possible reduction in tablet mass.
• A platform suitable for spray drying or hot-melt processing.

The risks include recrystallization during storage, sensitivity to humidity, polymer-regorafenib incompatibility, and a change in pharmacokinetic exposure. A dispersion that materially improves bioavailability may not qualify as a straightforward generic substitution.

Nanocrystal or particle-size engineering

Wet milling, bead milling, or controlled precipitation could produce smaller regorafenib particles and faster dissolution. This approach may preserve the immediate-release tablet concept while reducing dependence on high polymer loading.

The key development controls are:

• Particle-size distribution.
• Surface-area growth during storage.
• Residual solvent or milling-media control.
• Agglomeration.
• Dissolution in biorelevant media.
• Effects on peak plasma concentration.

Nanocrystal technology can create manufacturing know-how and process patents, but the regulatory burden increases if the product’s exposure profile differs from the reference product.

Lipid-based systems

Self-emulsifying or self-microemulsifying drug-delivery systems could address dissolution and gastrointestinal solubilization. These systems are more suitable for capsules, liquid-filled softgels, or specialized multiparticulate products than for a conventional compressed tablet.

Potential benefits include improved solubilization and reduced dependence on gastric dissolution. Commercial disadvantages include excipient tolerability, capsule-shell compatibility, oxidation control, scale-up complexity, and more difficult comparative dissolution testing.

Cyclodextrin and co-crystal approaches

Cyclodextrin complexes or pharmaceutical co-crystals could improve apparent solubility and physical stability. These approaches may support a differentiated 505(b)(2) product, but they are less attractive for a conventional ANDA if the formulation materially changes the active pharmaceutical ingredient’s solid-state behavior.

Precipitation-inhibiting excipients

A high-solubility formulation can fail when regorafenib precipitates after gastrointestinal dilution. Polymers such as hypromellose derivatives or povidone-based materials can inhibit precipitation. The relevant test is not only initial dissolution but also maintenance of supersaturation in biorelevant intestinal media.

This strategy may be useful where the development objective is improved absorption rather than merely faster tablet disintegration.

Modified-release systems

Modified release could reduce peak-related toxicity or smooth daily exposure. The clinical and regulatory burden is high, however. STIVARGA is an immediate-release product with a defined cyclic regimen. A modified-release product would likely require clinical pharmacology work beyond routine generic bioequivalence.

The strongest commercial case would be a formulation that reduces dose-limiting toxicity, improves adherence, or permits a more flexible dosing schedule.

What formulation patents could protect a STIVARGA opportunity?

A formulation patent is more defensible when it claims a technically specific solution rather than the use of a conventional excipient. Potential claim categories include:

Claim category	Potentially protectable subject matter
Solid state	Specific polymorph, amorphous form, co-crystal, or solid dispersion
Particle engineering	Defined particle-size range or surface-area profile
Composition	Regorafenib-to-polymer or regorafenib-to-lipid ratios
Dissolution	Defined dissolution performance under specified media and time points
Stability	Moisture-resistant formulation with defined impurity limits
Manufacturing	Spray drying, wet milling, granulation, or coating process
Dosage form	Multiparticulate, capsule, orally disintegrating tablet, or modified-release product
Clinical use	Reduced food effect, lower toxicity, or alternative dosing schedule

A patent that claims only "regorafenib with a pharmaceutically acceptable excipient" would face substantial validity and freedom-to-operate challenges. Stronger protection would link composition, process, physical properties, and measured performance.

Patent applicants should separate three commercial objectives:

• Generic substitution, where the product must closely match the reference product.
• Improved formulation, where clinical or pharmacokinetic differentiation supports a 505(b)(2) application.
• New therapeutic positioning, where a formulation enables a new dosing schedule, combination, or patient population.

How does an excipient strategy affect the FDA regulatory pathway?

ANDA strategy

An ANDA product must demonstrate pharmaceutical equivalence and bioequivalence to STIVARGA. A generic developer will generally favor the reference product’s immediate-release profile and use established excipients with prior oral-tablet safety experience.

The lowest-risk approach is:

• Same active ingredient and strength.
• Same dosage form.
• Similar release characteristics.
• Conventional excipients.
• Tight control of active-ingredient particle size.
• Comparative dissolution under multiple pH conditions.
• Fed and fasting pharmacokinetic evaluation where required.

A generic product does not need to use every branded excipient. It must meet applicable equivalence, quality, safety, and labeling requirements.

505(b)(2) strategy

A 505(b)(2) application could support a differentiated product with:

• Improved dissolution.
• Reduced food effect.
• Alternative dosage form.
• Reduced tablet burden.
• Modified-release delivery.
• A new dosing regimen.
• A clinically supported tolerability advantage.

This route can create more commercial value than an ANDA but usually requires additional clinical pharmacology or clinical evidence. It also increases formulation, patent, and market-access risk.

FDA inactive-ingredient considerations

Excipient selection must account for FDA precedent in oral solid dosage forms, maximum daily exposure, route of administration, and the proposed dosage form. The FDA Inactive Ingredient Database can support excipient selection, but the database does not eliminate the need for product-specific justification.[2]

What is the commercial opportunity for excipient suppliers?

The largest opportunity is likely to be supply into generic and differentiated regorafenib products rather than direct sales to the branded product. Relevant supplier categories include:

Supplier opportunity	Commercial rationale
High-functionality polymers	Improve solubility, supersaturation, and stability
Superdisintegrants	Accelerate tablet breakup and dissolution
Direct-compression excipients	Reduce manufacturing steps and cost
Film-coating systems	Replicate appearance and improve process control
Moisture-barrier coatings	Protect amorphous or highly hygroscopic systems
Lipid excipients	Support alternative solubilization technologies
Specialty silica	Improve flow and content uniformity
Co-processed excipients	Simplify scale-up and compression
Packaging systems	Reduce moisture exposure and support adherence

A supplier with a proprietary grade can capture value through formulation know-how, regulatory support, and preferred technical status. Commodity excipients such as standard microcrystalline cellulose, magnesium stearate, and titanium dioxide are more vulnerable to price competition.

How strong is the STIVARGA formulation patent estate?

The branded tablet’s publicly disclosed excipient composition is not, by itself, evidence of a strong formulation patent position. Patent strength depends on issued claims, enforceability, expiration dates, prosecution history, and whether the claims cover the marketed product rather than only broad concepts.

For commercial diligence, the relevant patent layers are:

1. Regorafenib compound patents.
2. Solid-form and polymorph patents.
3. Tablet-composition patents.
4. Manufacturing-process patents.
5. Method-of-use patents for approved indications.
6. Combination-treatment patents.
7. Regulatory exclusivity and Orange Book listings.

The FDA Orange Book is the primary source for listed patents and regulatory exclusivity associated with approved small-molecule products.[3] A generic applicant must separately assess non-Orange-Book patents, pending applications, foreign rights, trade secrets, and manufacturing know-how.

When does STIVARGA lose exclusivity and what generic entry risks exist?

STIVARGA’s principal commercial exposure comes from generic regorafenib, not biosimilars. U.S. entry depends on the expiration or successful challenge of relevant patents, the availability of an approved ANDA, and any settlement restrictions.

Paragraph IV risk

A Paragraph IV certification may challenge a listed patent on grounds that it is invalid, unenforceable, or not infringed. If the patent holder sues within the statutory period, FDA approval of the ANDA may be subject to a 30-month stay, subject to court and regulatory developments.[4]

Potential generic arguments may target:

• Non-infringement based on different excipients.
• Lack of novelty or obviousness for formulation claims.
• Failure of written description or enablement.
• Invalidity of broad solid-form claims.
• Expired compound or formulation claims.

Settlement risk

A settlement agreement could delay commercial launch, permit an authorized generic, or establish a licensed entry date. Settlement terms may materially change the value of a Paragraph IV challenge even when the underlying patent claims appear vulnerable.

Generic launch scenarios

Scenario	Market effect
Early ANDA approval with no enforceable blocking patent	Rapid price erosion and payer substitution
Single generic entrant	Moderate erosion, with temporary first-mover economics
Multiple generic entrants	Accelerated price compression
Authorized generic launch	Lower launch economics for independent challengers
505(b)(2) differentiated product	Slower substitution but potential premium pricing
No successful formulation differentiation	Commodity tablet competition

Exact launch timing requires current Orange Book data, court records, FDA approval status, and settlement terms. The regulatory label alone cannot establish a definitive commercial entry date.

Is there biosimilar risk for STIVARGA?

No. Regorafenib is a chemically synthesized small molecule, not a biologic. The relevant competitors are generic tablets, alternative oral dosage forms, and potentially reformulated regorafenib products.

Competitive pressure may also come indirectly from other targeted therapies used in the same treatment settings, including multikinase inhibitors, anti-VEGF agents, immunotherapies, and other treatments for colorectal cancer, GIST, and hepatocellular carcinoma.

How does STIVARGA compare with alternative commercial formulation opportunities?

Opportunity	Formulation complexity	Regulatory burden	Potential differentiation
Conventional generic tablet	Low to moderate	Moderate	Low
Improved immediate-release tablet	Moderate	Moderate to high	Moderate
Amorphous solid dispersion	High	High	High
Nanocrystal tablet	High	High	Moderate to high
Lipid capsule	High	High	High
Modified-release product	Very high	Very high	High
Lower-dose adherence pack	Low to moderate	Moderate	Commercial rather than technical
Combination or co-pack product	Moderate	High	Potentially high

The most practical near-term strategy is an equivalent immediate-release tablet using conventional excipients and controlled active-ingredient particle properties. The highest-value strategy is a differentiated formulation that addresses food effect, exposure variability, tablet burden, or tolerability.

What manufacturing and intellectual-property barriers matter most?

The principal barriers are:

• Regorafenib’s low solubility.
• Control of polymorphic or amorphous material.
• Reproducible dissolution across commercial batches.
• Stability under humidity and temperature stress.
• Scale-up of spray drying, milling, or granulation.
• Control of impurity formation.
• Demonstration of bioequivalence.
• Freedom to operate around solid-form and formulation claims.
• Reliable supply of specialty polymers or lipid excipients.

For a conventional generic, manufacturing efficiency and bioequivalence are the main value drivers. For a differentiated product, the defensible asset is more likely to be the formulation process and resulting physical-property profile than the identity of the excipient itself.

Key Takeaways

• STIVARGA is a 40 mg immediate-release regorafenib tablet taken in a four-tablet daily regimen after a low-fat meal.
• Its disclosed excipients are conventional: microcrystalline cellulose, croscarmellose sodium, povidone, colloidal silicon dioxide, magnesium stearate, and standard film-coating materials.
• The central formulation challenge is regorafenib’s low solubility and food-sensitive absorption.
• The strongest excipient opportunities involve amorphous solid dispersions, particle engineering, precipitation inhibition, lipid systems, and moisture protection.
• Generic developers will usually favor a conventional immediate-release formulation to limit ANDA and bioequivalence risk.
• A differentiated formulation may support a 505(b)(2) strategy but will require stronger pharmacokinetic, clinical, and patent support.
• Regorafenib has generic risk, not biosimilar risk.
• Excipient suppliers can capture value through specialty polymers, co-processed materials, manufacturing know-how, and regulatory support.
• Orange Book patents, Paragraph IV litigation, settlements, and current FDA approval status control the timing of generic entry.
• Public excipient disclosure alone does not establish a strong formulation patent estate.

FAQs

What is the best excipient for improving regorafenib dissolution?

A polymer-based amorphous solid dispersion is a leading technical option, but the best excipient depends on regorafenib loading, physical stability, dissolution conditions, and bioequivalence requirements.

Can a generic STIVARGA tablet use different excipients?

Yes. An ANDA product does not need to duplicate every inactive ingredient in the reference product. It must meet applicable pharmaceutical equivalence, bioequivalence, quality, safety, and labeling requirements.

Could regorafenib be developed as an orally disintegrating tablet?

Potentially. An orally disintegrating tablet could reduce swallowing burden, but the 160 mg daily dose creates a substantial tablet-mass challenge. Taste masking, dose loading, disintegration time, and exposure equivalence would be central development issues.

Would a lipid formulation avoid the STIVARGA low-fat meal requirement?

It could reduce food-effect sensitivity, but that outcome would require direct comparative pharmacokinetic evidence. A lipid formulation would likely be a differentiated product rather than a simple generic copy.

Which excipient technologies have the highest licensing value for regorafenib?

Technologies that improve dissolution while preserving exposure equivalence have the clearest licensing potential. Proprietary solid dispersions, nanocrystal processes, moisture-stable formulations, and reduced-food-effect systems are more commercially defensible than standard commodity excipients.

References

1. U.S. Food and Drug Administration. (2024). Stivarga (regorafenib) prescribing information. Bayer HealthCare Pharmaceuticals Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions-questions-and-answers